Aigen Investment Management LP Makes New Investment in Pfizer Inc. $PFE

Aigen Investment Management LP purchased a new position in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 83,314 shares of the biopharmaceutical company’s stock, valued at approximately $2,075,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Kepler Cheuvreux Suisse SA bought a new stake in shares of Pfizer during the 3rd quarter worth $16,613,000. Mackenzie Financial Corp raised its stake in shares of Pfizer by 119.6% during the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock worth $79,157,000 after purchasing an additional 1,691,773 shares during the period. Penn Davis Mcfarland Inc. raised its stake in shares of Pfizer by 50.9% during the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after purchasing an additional 57,777 shares during the period. Pzena Investment Management LLC raised its stake in shares of Pfizer by 0.9% during the 3rd quarter. Pzena Investment Management LLC now owns 6,615,598 shares of the biopharmaceutical company’s stock worth $168,565,000 after purchasing an additional 56,484 shares during the period. Finally, Ameriprise Financial Inc. raised its stake in shares of Pfizer by 48.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after purchasing an additional 5,978,927 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.1%

Shares of Pfizer stock opened at $26.19 on Friday. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The stock’s 50-day simple moving average is $26.43 and its 200 day simple moving average is $26.32. The stock has a market capitalization of $149.26 billion, a P/E ratio of 19.99 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date of this dividend was Friday, May 8th. Pfizer’s payout ratio is presently 131.30%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Bank of America lowered their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research note on Monday, March 2nd. HSBC lifted their target price on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Finally, Wolfe Research restated an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.82.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title
• Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title
• Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title
• Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title
• Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title
• Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.